Welcome to the Metabolon Blog!

We post commentary on all things metabolomics – from the latest publications to precision medicine. There are many exciting and growing metabolomics applications, so you never know what will inspire us to start writing. We invite you to subscribe and get each new post directly delivered to your inbox.

Metabolomics Approaches for NASH and NAFLD R&D

Apr 24, 2018, 8:11 AM
Metabolomics gives us valuable methods to compare preclinical model trials to human models of NASH. In this post, we share a case study with Gilead Sciences. More study is needed, but metabolomics may one day prove to outperform more invasive methods of assessing liver fibrosis, revealing opportunities to incorporate metabolomics into diagnostic tools.
Read more >

Research shows that acetaminophen has unexpected effects on regulation of sex hormones

Feb 23, 2018, 10:00 AM
A new study showed the potentially negative impact of the widely used, over-the-counter drug acetaminophen (paracetamol) on sex hormones, which has significant implications for reproductive health. It also highlights the power of genomic and metabolomic profiling to better understand drug mechanisms of action and metabolism even in common drugs such as acetaminophen.
Read more >

Exploring Human Metabolism to Map Genetic Influences

Oct 11, 2016, 8:57 AM
The metabolome describes all the small molecule metabolites in a single organism or biological sample and provides a snapshot of metabolic status at that particular moment. Combining the power of metabolomics with the genetic blueprint created by genome-wide association studies (GWAS) has allowed Metabolon and its collaborators to create an atlas of genetic influences on human blood metabolites.
Read more >

ASMS 2016: Round Up of Metabolon’s Presentations

Jun 14, 2016, 7:47 PM
The 64th American Society for Mass Spectrometry annual conference (ASMS) took place last week in San Antonio, TX. This meeting is always an important one for us.
Read more >

Using Metabolomics to Reduce Drug Attrition in Pharma R and D

Oct 4, 2015, 8:49 PM
It’s well-known that the time and cost to bring a new pharmaceutical to market are considerable. The average length of time from target ID to a new therapeutic is about 13 years and costs roughly $1.5 billion, embedded within an overall failure rate of 95%. But why?
Read more >

NOTIFICATIONS

Get notified when new posts are published!

Required